RPL17 and neoplasm: There is accumulating evidence of crosstalk between PD- 1/PD-L1 and interleukin (IL)− 1 pathways within the tumor microenvironment (TME), leading to treatment resistance to immune checkpoint inhibitors (ICIs) due to immunosuppression [3–6].